bmiMD vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Willow beats bmiMD overall, scoring 8.2/10 vs 8/10. Willow is more affordable at $299/mo vs $319/mo. Choose bmiMD for budget-first users who want affordable glp-1 access. Choose Willow for users who want comprehensive clinical support with flexibili.

A side-by-side comparison of bmiMD and Willow covering pricing, scores, medication types, insurance, and more to help you decide.

bmiMD

#9 of 48

8/10

Budget-friendly GLP-1 platform offering both medication types at one of the lowest price points in the market.

Visit bmiMD

Higher Rated

Willow

#8 of 48

8.2/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only — Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	bmiMD	Willow
Our Score	8/10	8.2/10
Starting Price	$319/mo	$299/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Budget-first users who want affordable GLP-1 access	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Ranking	#9	#8

Pros & Cons Compared

bmiMD

Pros

+Same-day physician consults — one of the few platforms offering telehealth appointments the same day you apply
+80,000+ customer base with 4.9-star Trustpilot rating provides strong social proof of reliability
+100% money-back guarantee if your consultation determines you don't qualify for GLP-1 treatment
+HSA/FSA accepted for all programs

Cons

−Starting at $289/mo for semaglutide — significantly more expensive than competitors at $99-199/mo
−$29.99 shipping fee per order — most competitors include free shipping
−$50 non-refundable cancellation fee after intake approval — penalizes patients who change their mind

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide — one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only — no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses — starting dose is $399/mo
−Cash-pay only — no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024 — less track record than Ro or Hims, though growth has been fast

Our Verdict

Willow edges out bmiMD with a score of 8.2/10 vs 8/10. If budget is your priority, Willow starts at $299/mo compared to bmiMD's $319/mo. bmiMD offers both brand-name and compounded medications, giving you more flexibility. Choose bmiMD if you want: budget-first users who want affordable glp-1 access. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

Still undecided? Editor's #1 Overall Pick

Eden Health GLP-1

$249/mo · 8.9/10 · Both

If neither bmiMD nor Willow feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Eden Health GLP-1 — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Eden Health GLP-1→Read our full Eden Health GLP-1 review